The Microscopy and Cell Analysis Core is fully equipped and expertly staffed to perform specimen preparation, light and electron microscopy, photography, digital imaging, and multi-parameter Flow and Cell Sorting services to Mayo Clinic Cancer Center investigators from both clinical and basic science laboratories. The facility also performs X-ray probe microanalysis, immuno-gold labeling, 3-D EM reconstruction from serial-sectioned specimens, and high-resolution reconstruction using image averaging of negative stained and cryo-tomography imaged specimens. Instrumentation and expertise are also supported in the core for high-end optical, two-photon, super-resolution, laser confocal, TIRF, ratio imaging, and other optical methods, as well as Flow Cytometry and Live Cell Sorting technologies and analysis. Additionally, the core staff (23 FTEs) and the core director are available for the development and/or implementation of new microscopy techniques and for testing and evaluation of instrumentation that would be of value to individual Mayo Cancer Center investigators and the greater research community. During the last budget year, the Microscopy and Cell Analysis Shared Resource has been widely utilized by each of the Mayo Cancer Center Programs. During the past 12 months, the facility served over 100 Mayo Cancer Center investigators processing 1000-plus specimens for electron microscopy, and logging 5,000 hours of Optical Microscopy and over 5000 hours of Flow Analysis and Cell Sorting. Because of the large expense for purchase and maintenance of high-end optical and electron microscopes, and the expertise required for their productive use, most investigators and their research laboratories find the Microscopy and Cell Analysis Core services to be the most economical, practical, and up-to-date means to achieve their sophisticated microscopy and cell sorting and analysis research needs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682943
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$280,370
Indirect Cost
$104,183
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications